ARIAD Pharma (ARIA) Posts Q2 Loss of 30c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Chardan Affirms ARIAD (ARIA) at 'Buy'; Narrower Label Impacts Iclusig Usage
August 7, 2014 10:26 AM EDTChardan Capital affirms ARIAD Pharma (Nasdaq: ARIA) at Buy with a $9 price target following Q2 results.
ARIAD posted Q2 revs of $12.1 million and loss of $0.30 per share, with Chardan at revs of $11.6 million and loss of $0.30 per share.
Analyst Ling Wang noted the following key points from the quarter:Iclusig is being used in later lines of patients impacted by a narrower label. Through 2Q14, ~550 patients in the U.S. received Iclusig in the commercial setting (with a weekly penetration of over 50%)... More
